Roots Analysis has done a detailed study on Antibody Contract Manufacturing Market, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.
To order this 285+ page report, which features 100+ figures and 110+ tables, please visit this link
Key Market Insights
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Types of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies
3.7. Overview of Contract Manufacturing
3.8. Need for Outsourcing in the Biopharmaceutical Industry
3.9. Advantages of Outsourcing Manufacturing Services
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Number of Employees
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Antibody Manufacturing Facilities
4.2.6. Analysis by Type of Antibodies Manufactured
4.2.7. Analysis by Expression Systems Used
4.2.8. Analysis by Regulatory Accreditations / Certifications
4.2.9. Additional Services Offered
5. COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Input Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
5.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
5.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AGC Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Future Outlook
6.3. Aldevron
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Future Outlook
6.4. AMRI
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Future Outlook
6.5. BioXcellence (Boehringer Ingelheim)
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Future Outlook
6.6. Emergent BioSolutions
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Future Outlook
6.7. Eurofins CDMO
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Manufacturing Facilities and Capabilities
6.7.4. Future Outlook
6.8. FUJIFILM Diosynth Biotechnologies
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Manufacturing Facilities and Capabilities
6.8.4. Future Outlook
6.9. KBI Biopharma
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Manufacturing Facilities and Capabilities
6.9.4. Future Outlook
6.10. Lonza
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Manufacturing Facilities and Capabilities
6.10.4. Future Outlook
6.11. Nitto Avecia Pharma Services
6.11.1. Company Overview
6.11.2. Service Portfolio
6.11.3. Manufacturing Facilities and Capabilities
6.11.4. Future Outlook
6.12. Novasep
6.12.1. Company Overview
6.12.2. Service Portfolio
6.12.3. Manufacturing Facilities and Capabilities
6.12.4. Future Outlook
6.13. Pierre Fabre
6.13.1. Company Overview
6.13.2. Service Portfolio
6.13.3. Manufacturing Facilities and Capabilities
6.13.4. Future Outlook
6.14. Samsung BioLogics
6.14.1. Company Overview
6.14.2. Service Portfolio
6.14.3. Manufacturing Facilities and Capabilities
6.14.4. Future Outlook
6.15. Synthon
6.15.1. Company Overview
6.15.2. Service Portfolio
6.15.3. Manufacturing Facilities and Capabilities
6.15.4. Future Outlook
6.16. Thermo Fisher Scientific
6.16.1. Company Overview
6.16.2. Service Portfolio
6.16.3. Manufacturing Facilities and Capabilities
6.16.4. Future Outlook
7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES
7.1. Chapter Overview
7.2. Small Molecule Drugs and Biologics
7.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
7.2.2. Comparison of Key Specifications
7.2.3. Comparison of Manufacturing Processes
7.2.4. Comparison of Key Manufacturing related Challenges
8. BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Region-wise Benchmarking
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Asia, Peer Group VII
8.3.8. Asia, Peer Group VIII
8.4. Concluding Remarks
9. PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnerships Models
9.3. Antibody Contract Manufacturing: List of Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis
- A steadily increasing demand for study participants and the complexities associated with patient enrollment has imposed
- The A Beka Publications were generated at Pensacola Christian School. They can be dependent on practical knowledge and data
- Professional-Cloud-Architect exam, Professional-Cloud-Architect exam dumps, Google Professional-Cloud-Architect exam, Professional-Cloud-Architect practice exam
- C_ARP2P_2005 exam | C_ARP2P_2005 exam dumps | SAP C_ARP2P_2005 exam | C_ARP2P_2005 practice exam | C_ARP2P_2005 actual exam | C_ARP2P_2005 braindumps | C_ARP2P_2005 questions & answers | C_ARP2P_2